First study of IMC-S118AI in adults with type 1 diabetes
Tests the safety of IMC-S118AI at rising doses in adults with type 1 diabetes.
Plain-language title generated from the registry record
Registry title: Study of IMC-S118AI in Type 1 Diabetes
Key facts
- Where
- Graz, AustriaSee the site
- Phase
- Phase 1
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults aged 18 to 45 with type 1 diabetes who carry the HLA-A*02:01 type and still show some beta-cell function.
- Age
- 18 to 45 years
- Sex
- All sexes can join.
- Disease stage
- Type 1 diabetes with signs of remaining beta-cell function.
- Earlier treatment
- People who had immune-modulating treatment for type 1 diabetes cannot join.
- Biomarker or test result
- HLA type HLA-A*02:01. Body mass index (BMI) of 18 to 25 kg/m2.
Main reasons for not taking part
- Diabetes that is not type 1 (type 2, monogenic or secondary diabetes)
- Repeated low blood sugar because insulin was not taken as prescribed
- Earlier immune-modulating treatment for type 1 diabetes
- History of heart disease or weak heart function
- Current or past cancer
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 45 years old?
Source: NCT07493122, who can take part
Where in Austria
- Medical University of GrazGraz, AustriaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Immunocore Ltd
- Trial code
- NCT07493122EU 2025-524449-28-00
- Record updated
- 25 March 2026
- Original description
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.Read full original descriptionShow less
A Dose-Escalation Study Evaluating the Safety and Pharmacokinetics of IMC-S118AI in HLA-A*02:01-Positive Participants With Type 1 Diabetes
This is a first-in-human (FIH) study designed to assess the safety, tolerability, and pharmacokinetic (PK) profile of IMC-S118AI in single-ascending dose (SAD) and multiple-ascending dose (MAD) regimens. This study will potentially also explore the effects of multiple-dosing regimens on preservation of beta-cell function in Stage 3 Type 1 diabetes.
Inclusion: Body mass index (BMI): 18 to 25 kg/m2; History of a diagnosis of T1D; HLA type: HLA-A*02:01; Shows signs of remaining beta-cell function.
Exclusion: Prior treatment with immunomodulating therapy for T1D; Non-T1D (type 2 diabetes, monogenic diabetes, and secondary diabetes); History of recurrent hypoglycaemia due to non-compliance with insulin regimens; Have a history of cardiovascular disease or impaired cardiac function; Current diagnosis of a malignancy or any history of malignancy.